Methaemoglobinaemia produced by phenazopyridine (Pyridium) in a man with chronic obstructive airways disease.
Life threatening methaemoglobinaemia developed after prolonged therapeutic use of phenazopyridine (Pyridium) in a patient with chronic obstructive airways disease. The combination of chronic obstructive airways disease and oxidant drugs (methaemoglobinaemia) may be lethal. The use of phenazopyridine should be abandoned. Certainly there is no indication to use it for more than a few days in any patient.
Chakraborty
T K
TK
Department of Medicine, Royal Infirmary of Edinburgh.
Filshie
R J
RJ
Lee
M R
MR
D000368:Aged; D000631:Aminopyridines / Q000009:adverse effects*; D002278:Carcinoma in Situ / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications; D008297:Male; D008708:Methemoglobinemia / Q000139:chemically induced*; D010621:Phenazopyridine / Q000009:adverse effects* / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000188:drug therapy*
D000631:Aminopyridines; D010621:Phenazopyridine